Drugs / KSQ-004EX
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06598371 | Nov 2024 → Aug 2039 expected | neoplasm | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KSQ-004EX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06598371 ↗ |
| Action | Inhibit | “Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1” NCT06598371 ↗ |
| Modality | Cell therapy | “Autologous Tumor Infiltrating Lymphocytes” NCT06598371 ↗ |
| Route | Intravenous | “Given by IV” NCT06598371 ↗ |
| Target | SOCS1 | “Inactivate Genes Encoding SOCS1” NCT06598371 ↗ |